VosMB, AbramsSH, BarlowSE, et al.NASPGHAN Clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr, 2017; 64:319–334.
2.
GoldnerD, LavineJE. Nonalcoholic fatty liver disease in children: Unique considerations and challenges. Gastroenterology, 2020; 158:1967–1983.e1.
3.
EslamM, AlkhouriN, VajroP, et al.Defining paediatric metabolic (dysfunction)-associated fatty liver disease: An international expert consensus statement. Lancet Gastroenterol Hepatol, 2021; 6:864–873.
4.
SchwimmerJB, DeutschR, RauchJB, et al.Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr, 2003; 143:500–505.
5.
Flisiak-JackiewiczM, Bobrus-ChociejA, WasilewskaN, LebensztejnDM. From nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD)-new terminology in pediatric patients as a step in good scientific direction?. J Clin Med, 2021; 10:1–11.
6.
YounossiZM, KoenigAB, AbdelatifD, et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016; 64:73–84.
7.
HegartyR, SinghS, BansalS, et al.NAFLD to MAFLD in adults but the saga continues in children: An opportunity to advocate change. J Hepatol, 2021; 74:991–992.
